3,4-Methylenedioxy Pyrovalerone-d₈ (hydrochloride)

3,4-Methylenedioxy pyrovalerone-d₈ (3,4-MDPV-d₈) (hydrochloride) (Item No. 10679) is intended for use as an internal standard for the quantification of 3,4-MDPV (Item No. 10684) by GC- or LC-MS. Pyrovalerone (Item No. 10817) and its analogs are inhibitors of the transporters for certain monoamine neurotransmitters, including dopamine and norepinephrine, preventing their uptake.^1,2 3,4-MDPV is an analog of pyrovalerone which includes the 3,4-methylenedioxy moiety found on 3,4-methylenedioxymethamphetamine, a DEA Schedule I controlled substance. While its physiological, neurological, and toxicological actions have not been characterized, 3,4-MDPV has been reported by the DEA to be abused as a central nervous system stimulant.³ Its effective dose and chemical interactions are unknown, but it has been used alone and in combination with other stimulating compounds. Products containing 3,4-MDPV have been marketed in Europe and Australia; they have also been seized by law enforcement in several states.³ 3,4-MDPV and some of its metabolites have recently been characterized by spectroscopic analysis.^4,5,6,7 3,4-MDPV is to be used in the forensic analysis of samples that may contain this compound. This product, the hydrochloride salt of 3,4-MDPV, has superior solubility in aqueous solvents, compared to the free base (Item No. 10624).

WARNING This product is not for human or veterinary use.

1. Heron, C., Costentin, J., and Bonnet, J.J. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur. J. Pharmacol. 264(3), 391-398 (1994).

2. Meltzer, P.C., Butler, D., Deschamps, J.R., et al. 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. J. Med. Chem. 49(4), 1420-1432 (2006).

3. U.S. Drug Enforcement Administration DEA, D.C.D. Methylenedioxypyrovalerone (MDPV) (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone]. (2010).

4. Westphal, F., Junge, T., Rosner, P., et al. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: A designer drug with α-pyrrolidinophenone structure. Forensic Sci. Int. 190(1-3), 1-8 (2009).

5. Meyer, M.R., Du, P., Schuster, F., et al. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J. Mass Spectrom. 45(12), 1426-1442 (2010).

6. Yohannan, J.C., and Bozenko, J.S. The characterization of 3,4-methylenedioxypyrovalerone (MDPV). Microgram J. 7(1), 12-15 (2010).

7. Strano-Rossi, S., Cadwallader, A.B., de la Torre, X., et al. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 24(18), 2706-2714 (2010).